Phase I study of 2-hydroxyoleic acid (2OHOA) in pediatric patients with malignant glioma and other advanced solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Mar 2020 According to a Laminar Pharma company website, Lipopharma has changed its name to Laminar Pharma.
29 May 2018 According to the Lipopharma media release, U.S. Food and Drug Administration has approved an Investigational New Drug application for this trial.
29 May 2018 According to the Lipopharma media release, this trial will be conducted in collaboration with two leading US paediatric clinical research institutions; Hackensack University Medical Center, in New Jersey and Dana-Farber Cancer Institute in Boston.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com